High Point, North Carolina (April 15, 2014) TransTech Pharma, LLC (“TransTech”) announced today that effective March 28, 2014, Stephen L. Holcombe, who previously served as the Company’s Senior Vice President and Chief Financial Officer, has been appointed to serve as the President of TransTech and
High Point, North Carolina (August 14, 2013) TransTech Pharma Inc. announced today important clinical trial data for its new diabetes drug. TTP399, a novel, liver-selective glucokinase activator (GKA), demonstrated clinical evidence of normalizing HbA 1c without inducing hypoglycemia in type 2
High Point, North Carolina (July 1, 2013) TransTech Pharma Inc. announced today that it has successfully completed an End of Phase 2 meeting for TTP488 with the U.S. Food and Drug Administration (FDA). TTP488 is under development for the treatment of mild to moderate Alzheimer’s disease.
High Point, North Carolina (March 18, 2013) TransTech Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for TTP488, a new small-molecule chemical compound being developed for the treatment of Alzheimer’s disease.
High Point, North Carolina (November 1, 2012) TransTech Pharma, Inc., announced today that recruitment of patients for its recently initiated, multi-center Phase 2 clinical trial of TTP054 in type 2 diabetics, is exceeding expectations with initial top line results available in early 2013.
High Point, North Carolina (October 29, 2012) A novel, orally administered drug candidate, TTP488, has demonstrated clinical evidence of slowing of cognitive decline over 18 months of therapy in patients with mild to moderate Alzheimer’s disease. TTP488 is a small-molecule drug that is the first to